{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Waibl Polania J"],"pubmed_abstract":["Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have evolved a variety of mechanisms to evade T cell-mediated killing. Thus, while many T cell-based immunotherapies, such as immune checkpoint inhibition (ICI) and chimeric antigen receptor (CAR) T cells, have achieved considerable success in some solid cancers and hematological malignancies, these therapies often fail in solid tumors due to tumor-imposed T cell dysfunctions. These dysfunctional mechanisms broadly include reduced T cell access into and identification of tumors, as well as an overall immunosuppressive tumor microenvironment that elicits T cell exhaustion. Therefore, novel, rational approaches are necessary to overcome the barriers to T cell function elicited by solid tumors. In this review, we will provide an overview of conventional immunotherapeutic strategies and the various barriers to T cell anti-tumor function encountered in solid tumors that lead to resistance. We will also explore a sampling of emerging strategies specifically aimed to bypass these tumor-imposed boundaries to T cell-based immunotherapies."],"journal":["Frontiers in immunology"],"pagination":["777073"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8636733"],"repository":["biostudies-literature"],"pubmed_title":["Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies."],"pmcid":["PMC8636733"],"pubmed_authors":["Fecci PE","Wilkinson DS","Lerner EC","Waibl Polania J","Hoyt-Miggelbrink A"],"additional_accession":[]},"is_claimable":false,"name":"Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.","description":"Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have evolved a variety of mechanisms to evade T cell-mediated killing. Thus, while many T cell-based immunotherapies, such as immune checkpoint inhibition (ICI) and chimeric antigen receptor (CAR) T cells, have achieved considerable success in some solid cancers and hematological malignancies, these therapies often fail in solid tumors due to tumor-imposed T cell dysfunctions. These dysfunctional mechanisms broadly include reduced T cell access into and identification of tumors, as well as an overall immunosuppressive tumor microenvironment that elicits T cell exhaustion. Therefore, novel, rational approaches are necessary to overcome the barriers to T cell function elicited by solid tumors. In this review, we will provide an overview of conventional immunotherapeutic strategies and the various barriers to T cell anti-tumor function encountered in solid tumors that lead to resistance. We will also explore a sampling of emerging strategies specifically aimed to bypass these tumor-imposed boundaries to T cell-based immunotherapies.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-22T08:09:51.402Z","creation":"2022-02-11T14:02:42.382Z"},"accession":"S-EPMC8636733","cross_references":{"pubmed":["34868044"],"doi":["10.3389/fimmu.2021.777073"]}}